Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

The American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction‐associated steatotic liver disease (MASLD).

• Publication year

  2023

• Venue

  Alimentary Pharmacology and Therapeutics

• Publication date

  2023-12-28

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/apt.17846PMID 38153279PMCID PMC10807722
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Changing epidemiology, global trends and implications for outcomes of NAFLD.

  2023cited by this paper
• Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease.

  2023cited by this paper
• Confirmatory biomarker diagnostic studies are not needed when transitioning from NAFLD to MASLD.

  2023cited by this paper
• Can we use old NAFLD data under the new MASLD definition?

  2023cited by this paper
• Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis

  2023cited by this paper
• A multisociety Delphi consensus statement on new fatty liver disease nomenclature

  2023cited by this paper
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

  2023cited by this paper
• A multi-society Delphi consensus statement on new fatty liver disease nomenclature.

  2023cited by this paper
• Natural history of NASH cirrhosis in liver transplant waitlist registrants.

  2023cited by this paper
• Changing global epidemiology of liver cancer from 2010 to 2019: NASH is the fastest growing cause of liver cancer.

  2022cited by this paper
• A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes.

  2022cited by this paper
• Global prevalence of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in the overweight and obese population: a systematic review and meta-analysis.

  2022cited by this paper
• Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.

  2022cited by this paper
• Easl Clinical Practice Guidelines (Cpgs) On Non-Invasive Tests For Evaluation Of Liver Disease Severity And Prognosis- 2020 Update.

  2021cited by this paper
• Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?

  2021cited by this paper
• Association of genetic variations with NAFLD in lean individuals

  2021cited by this paper
• The times they are a-changin' (for NAFLD as well).

  2020cited by this paper
• From NAFLD to MAFLD: Implications of a Premature Change in Terminology

  2020cited by this paper
• A new definition for metabolic associated fatty liver disease: an international expert consensus statement.

  2020cited by this paper
• Joint international consensus statement for ending stigma of obesity

  2020cited by this paper
• Animal models of NAFLD from the pathologist's point of view.

  2019cited by this paper
• Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease.

  2019cited by this paper
• EASL Clinical Practice Guidelines: Management of alcohol-related liver disease.

  2018cited by this paper
• International Association for the Study of Obesity

  2018cited by this paper
• Histological severity and clinical outcomes of nonalcoholic fatty liver disease in nonobese patients

  2017cited by this paper
• Pathogenesis and novel treatment options for non-alcoholic steatohepatitis.

  2016cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Forceon Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World HeartFederation; International Atherosclerosis Society; and International Asso

  2010cited by this paper
• Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International As

  2009cited by this paper
• Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B

  2008cited by this paper
• European Association for the Study of the Liver

  2006cited by this paper
• European Association for the Study of the Liver

  2006cited by this paper
• Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease.

  1980cited by this paper
• Fatty liver hepatitis and cirrhosis in obese patients.

  1979cited by this paper

• Multi-strain synbiotic and lifestyle modifications on patients with metabolic dysfunction-associated steatotic liver disease (MASLD): a randomized double-blinded placebo-controlled trial

  2026cites this paper
• Cholesterol: an ancient ally or modern menace?

  2026cites this paper
• Post-hoc analysis of a phase 2 randomized trial of pemafibrate in metabolic dysfunction-associated steatotic liver disease: associations with platelet count, liver stiffness, and spleen volume.

  2026cites this paper
• Waist Circumference as a Predictor of Hepatic Steatosis and Fibrosis in the NHANES 2017-2018 Cohort.

  2026cites this paper
• Metabolic dysfunction-associated steatotic liver disease: Prevalence and progression in lean patients

  2025cites this paper
• Approach to steatotic liver disease in the office

  2025cites this paper
• Approche de la stéatose hépatique en clinique

  2025cites this paper
• Targeting CRM1-HMGB1 Nuclear Translocation in Type 2 Diabetes-Driven Metabolic Dysfunction Associated Steatotic Liver Disease

  2025cites this paper
• From Childhood Obesity to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Hyperlipidemia Through Oxidative Stress During Childhood

  2025cites this paper
• Longitudinal Clinical Outcomes and Mortality from Steatotic Liver Disease: A Meta-Analysis.

  2025cites this paper
• Serum polychlorinated biphenyls as a risk factor for MASLD: Exploring the association and underlying mechanisms.

  2025cites this paper
• Lights and Shadows of a Vegetarian Diet in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease

  2025cites this paper
• CNN-Based Analytical Approach for Liver Disease Classification and Prediction

  2025cites this paper
• All-cause and disease-specific mortality in young adults with MASLD: A nationwide cohort study

  2025cites this paper
• Medical Implications of Renaming Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

  2025influential citation
• Managing Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) in Primary Care Settings: A Review

  2025cites this paper
• Associations between serum uric acid related ratios and the onset of metabolic dysfunction associated steatotic liver disease

  2025cites this paper
• Beyond BMI: revealing metabolic risk in lean MASLD

  2025cites this paper
• Preventive Effect of Eicosapentaenoic Acid on the Exacerbation of Concanavalin A-Induced Liver Injury Aggravated by a Short-term High-fat Diet.

  2025cites this paper
• Associations between steatotic liver disease subtypes and incident atrial fibrillation in young adults: a nationwide cohort study

  2025cites this paper
• Metabolic Dysfunction-Associated Steatotic Liver Disease as a Risk Factor for Chronic Kidney Disease: A Narrative Review

  2025cites this paper
• Associations of Sociodemographic Factors, Healthy Habits, and Weight Stigma With Non-Alcoholic Fatty Liver Disease Risk in Obese Workers: Findings From a Large Occupational Cohort.

  2025cites this paper
• BIO-ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF TENELIGLIPTIN, REMOGLIFLOZIN ETABONATE AND ITS APPLICATION TO PHARMACOKINETIC STUDIES IN RAT PLASMA BY USING LC-MS/MS

  2025cites this paper
• Screening of advanced fibrosis and metabolic dysfunction-associated steatotic liver disease using transient elastography in vulnerable population

  2025cites this paper
• Time Restricted Hypo-caloric Diet Achieves Better Insulin Sensitivity over Hypo-caloric Diet Alone in Patients With Metabolic Dysfunction-associated Steatotic Liver Disease: A Randomized Controlled Trial.

  2025cites this paper
• Hepatic complications of type 1 diabetes mellitus in children. A review

  2025cites this paper
• From steatosis to cirrhosis: the role of obesity in the progression of liver disease

  2025cites this paper
• Association of aspirin use alone with mortality and liver-related events in MASLD: a multi-institutional three-year study

  2025cites this paper
• Diagnostic Performance of Ultrasound-Derived Fat Fraction and Automated Point Shear Wave Elastography for Hepatic Steatosis and Fibrosis in Suspected Steatotic Liver Disease: A Prospective Multicenter Study.

  2025cites this paper
• Dietary and Lifestyle Interventions for Steatotic Liver Disease Associated with Metabolic Dysfunction

  2025cites this paper
• Identification and Validation of Lipid Metabolism-Related Biomarkers GPD1 and CEBPD in Metabolic Dysfunction-Associated Steatohepatitis

  2025cites this paper
• Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future Approaches.

  2025cites this paper
• Editorial: MetALD and Risk of Gastrointestinal Cancer-What Can We Learn From Japan? Authors' Reply.

  2025cites this paper
• A Message From the Editors

  2025cites this paper
• MASLD and viral hepatitis overlap: An emerging dual burden in chronic liver disease

  2025cites this paper
• Oxidative Stress in Liver Metabolic Dysfunction and Diseases, with a Focus on Hepatogenic Diabetes: Effect of Alcohol Consumption

  2025cites this paper
• Insulin-Like Growth Factor-1 (IGF-1) Deficiency and Metabolic-Dysfunction-Associated Steatotic Liver Disease in a Young Patient

  2025cites this paper
• FucoVital® inhibits fatty acid accumulation in liver cells in vitro and reduces triglycerides levels in patients with NAFLD

  2025cites this paper
• Correlation between metabolic dysfunction-associated steatotic liver disease and subclinical coronary atherosclerosis in eastern China

  2025cites this paper
• Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD through the COVID-19 pandemic: Editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017–2023”

  2025cites this paper
• Effects of Selected Food Additives on the Gut Microbiome and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)

  2025cites this paper
• Focused Recommendations for the Management of Metabolic Dysfunction-Associated Steatohepatitis (MASH) by Advanced Practice Providers in the United States

  2025cites this paper
• Muscle Strength and Cardiovascular Health in MASLD: A Prospective Study

  2025cites this paper
• The Lipidomic Profile Discriminates Between MASLD and MetALD

  2025cites this paper
• Metabolic Dysfunction and Alcohol-Associated Liver Disease: A Narrative Review

  2025cites this paper
• Addressing the High and Rising Global Burden of Metabolic Dysfunction‐Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction‐Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective

  2025cites this paper
• Global burden and risk factors of MASLD: trends from 1990 to 2021 and predictions to 2030

  2025cites this paper
• Gut Microbiota and Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Emerging Pathogenic Mechanisms and Therapeutic Implications

  2025cites this paper
• From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management

  2025cites this paper
• Resmetirom: The First Disease-Specific Treatment for MASH

  2025cites this paper
• The new definition of metabolic dysfunction-associated steatotic liver disease: the role of ultrasound and elastography

  2025cites this paper
• Effects of Pemafibrate on Serum Carnitine and Plasma Myostatin in Patients With Metabolic Dysfunction Associated Steatotic Liver Disease

  2025cites this paper
• High Global Prevalence of Steatotic Liver Disease and Associated Subtypes: a Meta-Analysis.

  2025cites this paper
• New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice

  2024cites this paper
• Defining omic-based biomarker signatures of metabolic dysfunction-associated steatotic liver disease (MASLD): in vitro studies

  2024cites this paper
• Non-alcoholic fatty liver disease and coexisting depression, anxiety and/or stress in adults: a systematic review and meta-analysis

  2024cites this paper
• Editorial: Crystalising the burden of steatotic liver disease—Authors' reply

  2024cites this paper
• Update on the development of TGR5 agonists for human diseases.

  2024cites this paper
• Evaluación comparativa de APRI, FIB-4, HFS y NFS: herramientas de puntuación para la fibrosis hepática en la población mexicana con MASLD

  2024cites this paper
• Non-invasive Scores and Serum Biomarkers for Fatty Liver in the Era of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD): A Comprehensive Review From NAFLD to MAFLD and MASLD

  2024cites this paper
• Prognostic Impact of Metabolic Syndrome and Steatotic Liver Disease in Hepatocellular Carcinoma Using Machine Learning Techniques

  2024cites this paper
• Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis

  2024cites this paper
• The effect of vitamin E and docosahexaenoic acid ethyl ester on Metabolic Dysfunction‐Associated steatotic Liver Disease (MASLD)—A randomised, double‐blind, placebo‐controlled, parallel‐group clinical trial (PUVENAFLD)

  2024cites this paper
• Disparities for Hispanic Adults with metabolic dysfunction-associated steatotic liver disease in the US: A Systematic Review and Meta-analysis.

  2024cites this paper
• Impact of peripheral thyroid hormone balance on liver fat: insights from the NutriAct trial.

  2024cites this paper
• Global prevalence of nonalcoholic fatty liver disease: an updated meta-analysis on 78 million population over 38 countries.

  2024cites this paper
• Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease

  2024cites this paper
• Role of Neutrophils in the Development of Steatotic Liver Disease

  2024cites this paper
• Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA

  2024cites this paper
• Lights and shadows in the new definition of steatotic liver disease.

  2024cites this paper
• Associations of Cannabis Use, Metabolic Dysfunction-Associated Steatotic Liver Disease, and Liver Fibrosis in U.S. Adults

  2024cites this paper
• Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study

  2024cites this paper
• Comparative evaluation of APRI, FIB-4, HFS, and NFS: Scoring tools for liver fibrosis in a Mexican population with MASLD.

  2024cites this paper
• Metabolic dysfunction-associated steatotic liver disease: a key factor in hepatocellular carcinoma therapy response

  2024cites this paper
• Cardiometabolic phenotype linked to fibrosis and mortality in metabolic dysfunction-associated steatotic liver disease.

  2024cites this paper
• Letter: Towards Better Intervention Strategies for MASLD and MetALD—What Are We Missing? Authors' Reply

  2024cites this paper
• Editorial: Metabolic Dysfunction and Alcohol—Two Sides of the Same Coin

  2024cites this paper
• From adiposity to steatosis: metabolic dysfunction-associated steatotic liver disease, a hepatic expression of metabolic syndrome – current insights and future directions

  2024cites this paper
• Effects of Pemafibrate on LDL-C and Related Lipid Markers in Patients with MASLD: A Sub-Analysis of the PEMA-FL Study

  2024influential citation
• Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population

  2024cites this paper
• Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States—Authors' reply

  2024cites this paper
• 2024 UPDATE: the Brazilian Diabetes Society position on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) in people with prediabetes or type 2 diabetes

  2024cites this paper
• Impact of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) on the expression and function of hepatobiliary transporters: A comprehensive mechanistic review.

  2024cites this paper
• Nonalcoholic steatohepatitis: A comprehensive updated review of risk factors, symptoms, and treatment

  2024cites this paper
• World Journal of Hepatology

  year unknowncites this paper